Selection of an antidepressant: Mirtazapine

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 6, 1997, Pages 3-8

  Preskorn, Sheldon H ^a,b  

^a University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE MALEATE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PHENELZINE; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE;

ARTICLE; BIOTRANSFORMATION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; MEDICAL DECISION MAKING; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOTRANSFORMATION; CLINICAL TRIALS; DECISION MAKING; DEPRESSIVE DISORDER; HUMANS; MIANSERIN; PATIENT SELECTION; RECEPTORS, NEUROTRANSMITTER;

EID: 0030792394     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Preskorn SH. Should rational drug development in psychiatry target more than one mechanism of action in a single molecule? International Review of Psychiatry 1995;7:17-28
2. Frazer A. Antidepressants. J Clin Psychiatry 1997;58(suppl 6):9-25
3. Sambunaris A, Keppel Hesselink J, Pinder R, et al. Development of new antidepressants. J Clin Psychiatry 1997;58(suppl 6):40-53
4. Nelson JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry 1997;58(suppl 6):26-31
5. Fawcett J, Barkin RL. Efficacy issues with antidepressants. J Clin Psychiatry 1997;58(suppl 6):32-39
6. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994;114:559-565
7. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52:1023-1029
8. 2-selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission. Human Psychomarmacology 1995;10: S107-S118
9. Preskorn S, Fast G. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991;52(6, suppl): 23-33
10. Preskorn SH. Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. 1st ed. Caddo, Okla: Professional Communications; 1996
11. Hoyer D, Clarke D, Fozard J, et al. VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203
12. Peroutka SJ, Sleight AJ, McCarthy BG, et al. The clinical utility of pharmacologic agents that act at serotonin receptors. Journal of Neuropsychiatry 1989;3:253-262
13. Peroutka S. 5-hydroxytryptamine receptor subtypes: molecular, biochemical, and physiological characterization. Trends Neurosci 1989;11:496-500
14. Bergeron R, Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry 1994;151: 1084-1086
15. Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994;151:1069-1072
16. Catterson M, Preskorn SH. Double blind crossover study of mirtazapine, amitriptyline and placebo in patients with major depression. In: New Research Program and Abstracts of the 149th Annual Meeting of the American Psychiatric Association; May 6, 1996; New York, NY. Abstract NR157
17. Dahl M-L, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 1997;13:37-46